논문KCI 등재
Correspondence to editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
참고문헌 (11)
관련 논문AI추천
Targeting TM4SF1 to overcome immunotherapy resistance in hepatocellular carcinoma: Editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”Valerie Chew대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호TM4SF1 - A new immune target for treatment of hepatocellular carcinoma: Editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”Chen Rui Yuan, Terence Kin Wah Lee대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호Tetraspan(in)-mediated immune regulation in hepatocellular carcinoma: Editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”Dong Joo Kim, Jung Weon Lee, Seo Hee Jin대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”Ahmed O. Kaseb, Ji Hoon Kim, Ju-Seog Lee, Sung Hwan Lee, Sunyoung S. Lee, Sun Young Yim대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”Ahmed O. Kaseb, Ji Hoon Kim, Ju-Seog Lee, Sung Hwan Lee, Sunyoung S. Lee, Sun Young Yim대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Correspondence to editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”Karin Wisskirchen, Ke Zhang, Shunda Du, Ulrike Protzer대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호
이 간행물의 다른 논문 (84건)
Epidemiology of metabolic dysfunction-associated steatotic liver diseaseLinda Henry, Markos Kalligeros, Zobair M. Younossipp. 32-50Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver diseaseJimmy Che-To Lai, Sherlot Juan Song, Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Yichong Jiang, Yue Wangpp. 51-75Precision medicine and nucleotide-based therapeutics to treat steatotic liver diseaseAndrea Caddeo, Stefano Romeopp. 76-93Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver diseaseJasmohan S. Bajaj, Jeremy Burton, Antonio Gil-Gómez, Huma Saeed, Juan Pablo Arab, Luis Antonio Díaz, Manuel Romero-Gomez, Marco Arrese, Mohammad Qasim Khanpp. 94-111Alcohol-associated liver disease: Natural history, management and novel targeted therapiesHugo López-Pelayo, Edilmar Alvarado-Tapias, Ana Clemente-Sánchez, Ramón Bataller, Jordi Gratacós-Ginès, Elisa Posepp. 112-133